Because SS is known to overexpress BCL-2 and venetoclax-based combination therapies are very effective across multiple hematological cancers, we chose to focus on deciphering the role of BCL-2 family members in this cancer. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.